Glenmark Pharmaceuticals presents new data on Ryaltris

06 Mar 2018 Evaluate

Glenmark Pharmaceuticals has presented new data on Ryaltris, an investigational fixed-dose combination nasal spray for Seasonal Allergic Rhinitis (SAR), at the AAAAI/WAO Joint Congress in Orlando, Florida.

New data was studied on more than 2,400 patients to 14 days of twice-daily treatment with Ryaltris or placebo. Ryaltris (mometasone furoate (25 mcg) and olopatadine hydrochloride (665 mcg)), formerly GSP 301 Nasal Spray, is Glenmark’s leading respiratory candidate with a New Drug Application filing anticipated in the first half of 2018.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2006.90 -71.40 (-3.44%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×